Drug intelligence / Profile preview

EP102

Development stage: Phase 1
Lead developer: EPICS Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

EP102 is an investigational, orally administered small molecule developed by Epics Therapeutics. It functions as a potent and selective inhibitor of the METTL3 enzyme, which is responsible for catalyzing N6-methyladenosine (m6A) modifications on RNA. By blocking METTL3, EP102 aims to reprogram tumor biology by modulating RNA signaling that sustains tumor growth and enhances metastatic potential, representing a novel approach to target cancer at the RNA level. It is currently in a first-in-human Phase 1 clinical trial for participants with advanced solid tumors.

Targets

METTL3 (Methyltransferase-like protein 3)

Beyond the preview

Go deeper on EP102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EP102.

Explore the full profile